CD274 and melanoma: In a meta-analysis, the authors divided patients into NSCLC group and other cancer groups (melanoma, prostate cancer), that is, based on the cancer types and indicated that PD-1/PD-L1 inhibitors have no significant differences in cardiotoxicity compared with chemotherapy or placebo[25].